Novo Nordisk (NVO) has "more than enough" Wegovy pills in anticipation of approval of the weight-loss drug's pill version in the US before year-end, Reuters reported Monday, citing Chief Executive Officer Mike Doustdar.

Reuters said Doustdar issued the statement during a Monday event hosted by the Danish Shareholders Association. According to the report, the company aims to prevent the supply issues it previously had with Wegovy injection, the current formulation approved by the US Food and Drug Administration.

Novo Nordisk did not immediately respond to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)